Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.
Cognitive impairment is common also in early stages of MS, but only little is known about its relationship to standard immunotherapeutic drugs. Present data suggest that both immunosuppressive as well as immunomodulatory therapy prevent or delay the onset and severity of cognitive impairment although reversible cognitive deficits can occur.